GUTS Earning Date, Earning Analysis and Earning Prediction

Quarterly Results

GUTS Earnings Forecast

Looking ahead, GUTS remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of -0.18.

However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been unchanged by 0%, while EPS estimates have been unchanged by 0%. For the upcoming , revenue estimates have been adjusted revised downward by -80.94%. These revisions correlate with a 0% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in GUTS long-term fundamentals.

The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

RevenueEPS

Currency: USD

Revenue Estimate-:0

EPS Estimate-:0

—

Stock Price0

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-80.94%

In Past 3 Month

No data

Earnings Surprise Analysis

Revenue

EPS

AI Analysis

Earnings Reaction

The chart below shows how GUTS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GUTS sees a 15.47% change in stock price 10 days leading up to the earnings, and a 8.71% change 10 days following the report. On the earnings day itself, the stock moves by -0.04%. This data can give you a slight idea of what to expect for the next quarter's release.

For example, in DEC/2025, the stock changed 16.17% on the day following the earnings release and then changed by -0.79% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of GUTS's latest earnings report for ?

GUTS reported its earnings on 2026-03-24, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was 0.15, surpassing the expected -0.19 by 178.95%. The stock experienced a 16.17% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did GUTS's stock price react after the earnings release?

Following GUTS's earnings announcement on 2026-03-24, the stock price moved by 16.17% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GUTS's stock price tends to shift by an average of 15.47% in the 10 days leading up to earnings and 8.71% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for GUTS for ?

For , analysts estimate GUTS's annual revenue to reach , while the EPS is projected at -0.18. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -80.94% over the past three months, indicating analyst expectation in the company's performance.

How does GUTS's stock price correlate with earnings forecast revisions?

The correlation between GUTS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -80.94%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from GUTS's next earnings report?

Based on historical trends, GUTS's stock price typically moves by 15.47% in the 10 days before its earnings and 8.71% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.18 and revenue of .

What is the sentiment in Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Summary?

The earnings call presents mixed signals. Basic financial performance shows decreased R&D expenses but increased SG&A, and a significant noncash net loss. Product development updates are positive, with confidence in pivotal study results. Market strategy faces hurdles with reimbursement pathways. Financial health is stable with cash to fund operations till 2027. Shareholder returns were not discussed. The Q&A reveals positive sentiment towards ablation efficacy but management's avoidance of specifics on secondary endpoints raises concerns. Overall, the mixed financials and strategic uncertainties balance out the positive product developments, leading to a neutral sentiment.